glp-1 drugs and multiple sclerosis Ozempic Sclerosis: Insights From Dr. Aaron Boster on Agonists Episode 444: A GLP-1 Drug
Description
GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health
Manufactured in a cGMP-certified, FDA-registered facility in Utah
Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios
Subtle support that works with your habits, not against them
Thirteen trials involving 5,807 participants were identified
The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7%
